GlassScriptPhysician profile
Shehzad Sami
NPI 1033147517
$4,817.43
in general payments reported to CMS, 2019-2025
23 companies · $778 in 2025
The $778 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $811 · 2020: $497 · 2021: $631 · 2022: $1,069 · 2023: $509 · 2024: $523 · 2025: $778.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,809.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,809.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,401.40 | 2019-2025 | Xact, Aveir |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $567.09 | 2019-2025 | Lifevest |
| Shockwave Medical, INC | $464.07 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boston Scientific Corporation | $437.71 | 2019-2025 | Mylux Patient Kit With Mobile Device, Avvigo Guidance System, Watchman Flx |
| Esperion Therapeutics, INC. | $369.77 | 2020-2025 | Nexletol |
| Amgen INC. | $350.53 | 2019-2025 | Repatha |
| Novartis Pharmaceuticals Corporation | $249.77 | 2022-2025 | |
| Pfizer INC. | $162.51 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $123.59 | 2022-2025 | Camzyos, Eliquis |
| Heartflow, INC. | $94.98 | 2019-2022 | |
| Medtronic, INC. | $90.68 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.55 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $72.31 | 2022-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $66.04 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $58.18 | 2022-2023 | Verquvo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $51.61 | 2019 | |
| Novo Nordisk INC | $45.70 | 2024-2025 | Wegovy |
| Cardiovascular Systems INC. | $33.47 | 2022 | |
| Alnylam Pharmaceuticals INC. | $29.14 | 2021 | |
| Sanofi-Aventis U.S. LLC | $20.50 | 2021 | |
| Validus Pharmaceuticals LLC | $18.42 | 2025 | Raldesy |
| Cleerly, INC. | $15.94 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Cardiva Medical, INC. | $11.47 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shehzad Sami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.